CD5024 0.3% cream — Competitive Intelligence Brief

CD5024 0.3% cream (CD5024 0.3% cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: calcineurin inhibitor. Area: Dermatology.

phase 2 calcineurin inhibitor calcineurin Dermatology Small molecule

Target snapshot

CD5024 0.3% cream (CD5024 0.3% cream) — Galderma R&D. CD5024 0.3% cream is a topical calcineurin inhibitor that suppresses the immune system by inhibiting T-cell activation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CD5024 0.3% cream TARGET	CD5024 0.3% cream	Galderma R&D	phase 2	calcineurin inhibitor	calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
Branded Tacrolimus	Branded Tacrolimus	Novartis	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
Prograf (Tacrolimus)	Prograf (Tacrolimus)	East Carolina University	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
Tacrolimus/MMF	Tacrolimus/MMF	University of Miami	marketed	Immunosuppressant combination	Calcineurin (tacrolimus); IMPDH type II (MMF)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2027-11-03 — Sandimmune · 8298568 · Formulation · US
• 2029-06-02 — Sandimmune · 9132071 · Formulation · US
• 2030-12-13 — Sandimmune · 8614178 · Formulation · US
• 2031-02-25 — Sandimmune · 8292129 · Formulation · US
• 2032-04-16 — Sandimmune · 8561859 · Formulation · US
• 2033-08-23 — Sandimmune · 8980839 · Formulation · US
• 2033-08-23 — Sandimmune · 10441630 · Formulation · US
• 2033-08-23 — Sandimmune · 9937225 · Formulation · US
• 2034-02-07 — Sandimmune · 9676525 · Formulation · US
• 2034-05-11 — Sandimmune · 9669974 · Formulation · US
• 2036-09-29 — Sandimmune · 12496326 · Method of Use · US
• 2037-02-28 — Sandimmune · 11951153 · Method of Use · US
• 2037-02-28 — Sandimmune · 10918694 · Formulation · US
• 2037-09-22 — Sandimmune · 10813976 · Formulation · US
• 2038-11-20 — Sandimmune · 11154513 · Formulation · US
• 2039-10-11 — Sandimmune · 11413323 · Method of Use · US
• 2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (calcineurin inhibitor class)

1. Sanofi · 2 drugs in this class
2. Fovea Pharmaceuticals SA · 1 drug in this class
3. Galderma R&D · 1 drug in this class
4. Glenmark Pharmaceuticals Ltd. India · 1 drug in this class